Xenon Pharmaceuticals Inc. (XENE)
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
Driehaus Capital Management increased its XENE stake by 369,577 shares in the fourth quarter; the estimated transaction value was $15.52 million. Meanwhile, the quarter-end position value rose by $36.03 million, reflecting both trading and price appreciation.
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but follow major news that has led investors to re-rate each stock.
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked
Xenon Pharmaceuticals Inc. surged on positive Phase 3 data for azetukalner in focal onset seizures, showing best-in-class placebo-adjusted efficacy. XENE plans an NDA submission for azetukalner in Q3 2026, targeting both epilepsy and neuropsychiatric indications, with additional pivotal trials ongoing. Despite robust efficacy and a differentiated profile, XENE faces a crowded anti-seizure market, notable adverse event rates, and potential commercial execution risks.
Xenon Pharma's epilepsy drug meets main goal in late-stage trial
Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of a late-stage trial, showing a statistically significant reduction in focal onset seizures.
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercial upside.
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
